Raras
Buscar doenças, sintomas, genes...
Alteração do glicosfingolipídio e glicosilação da âncora glicosilfosfatidilinositol
Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Doença rara que afeta a produção de glicosfingolipídios e a âncora glicosilfosfatidilinositol, manifestando-se com alterações neurológicas (desmielinização, convulsões), hepáticas e malformações esqueléticas. Causada por mutações em genes como PIGT e ST3GAL5.

🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
65 sintomas
🦴
Ossos e articulações
51 sintomas
😀
Face
45 sintomas
🫃
Digestivo
28 sintomas
👁️
Olhos
26 sintomas
🧬
Pele e cabelo
19 sintomas

+ 177 sintomas em outras categorias

Características mais comuns

Pectus excavatum
Concentração elevada de alanina aminotransferase circulante
Crus superior da anti-hélice proeminente
Sialorreia
EEG com poliespículas generalizadas
Hipoplasia da substância branca cerebral
507sintomas
Sem dados (507)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 507 características clínicas mais associadas, ordenadas por frequência.

Pectus excavatum
Concentração elevada de alanina aminotransferase circulanteElevated circulating alanine aminotransferase concentration
Crus superior da anti-hélice proeminenteProminent superior crus of antihelix
SialorreiaDrooling
EEG com poliespículas generalizadasEEG with generalized polyspikes

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa3
Últimos 10 anos1publicações
Pico20231 papers
Linha do tempo
2023Hoje · 2026
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

13 genes identificados com associação a esta condição.

PIGTGPI-anchor transamidase component PIGTDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Component of the glycosylphosphatidylinositol-anchor (GPI-anchor) transamidase (GPI-T) complex that catalyzes the formation of the linkage between a proprotein and a GPI-anchor and participates in GPI anchored protein biosynthesis (PubMed:11483512, PubMed:12582175, PubMed:28327575, PubMed:34576938, PubMed:35165458, PubMed:35551457, PubMed:36970549, PubMed:37684232). May play a crucial role in GPI-T complex assembly in the luminal layer (PubMed:35165458, PubMed:35551457). Binds GPI-anchor (PubMed

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Attachment of GPI anchor to uPAR
MECANISMO DE DOENÇA

Multiple congenital anomalies-hypotonia-seizures syndrome 3

An autosomal recessive syndrome characterized by distinct facial features, intellectual disability, hypotonia and seizures, in combination with abnormal skeletal, endocrine, and ophthalmologic findings including impaired vision, as well as abnormal motility of the eyes.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
53.6 TPM
Artéria coronária
42.9 TPM
Artéria tibial
38.8 TPM
Útero
35.9 TPM
Fibroblastos
35.5 TPM
OUTRAS DOENÇAS (2)
multiple congenital anomalies-hypotonia-seizures syndrome 3paroxysmal nocturnal hemoglobinuria 2
HGNC:14938UniProt:Q969N2
PIGLN-acetylglucosaminyl-phosphatidylinositol de-N-acetylaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalyzes the second step of glycosylphosphatidylinositol (GPI) biosynthesis, which is the de-N-acetylation of N-acetylglucosaminyl-phosphatidylinositol

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Coloboma, congenital heart disease, ichthyosiform dermatosis, impaired intellectual development, and ear anomalies syndrome

An extremely rare autosomal recessive multisystem disorder clinically characterized by colobomas, congenital heart defects, migratory ichthyosiform dermatosis, intellectual disability, and ear anomalies including conductive hearing loss. Other clinical features include distinctive facial features, abnormal growth, genitourinary abnormalities, seizures, and feeding difficulties.

EXPRESSÃO TECIDUAL(Ubíquo)
Cervix Endocervix
16.6 TPM
Skin Sun Exposed Lower leg
14.9 TPM
Nervo tibial
14.8 TPM
Tireoide
14.1 TPM
Mama
13.1 TPM
OUTRAS DOENÇAS (2)
CHIME syndromehyperphosphatasia-intellectual disability syndrome
HGNC:8966UniProt:Q9Y2B2
PIGGGPI ethanolamine phosphate transferase 2, catalytic subunitDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of the ethanolamine phosphate transferase 2 complex that transfers an ethanolamine phosphate (EtNP) from a phosphatidylethanolamine (PE) to the 6-OH position of the second alpha-1,6-linked mannose of a 2-acyl-6-[6-phosphoethanolamine-alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-2-phosphoethanolamine-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl]-1-(1-radyl,2-acyl-sn-glycero-3-phospho)-1D-myo-inositol (also termed H7) intermediate to generate a 2-acyl-6-[6-phosphoethanolamine-

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Neurodevelopmental disorder with or without hypotonia, seizures, and cerebellar atrophy

An autosomal recessive disorder characterized by delayed psychomotor development, hypotonia, and early-onset seizures in most patients. Additional variable features are cerebellar atrophy, ataxia, and non-specific dysmorphic features. Some patients may have the Emm-null blood group phenotype.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
22.4 TPM
Ovário
21.7 TPM
Nervo tibial
21.4 TPM
Útero
19.8 TPM
Fibroblastos
19.5 TPM
OUTRAS DOENÇAS (2)
intellectual disability, autosomal recessive 53Wolf-Hirschhorn syndrome
HGNC:25985UniProt:Q5H8A4
ST3GAL5Lactosylceramide alpha-2,3-sialyltransferaseDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Transfers the sialyl group (N-acetyl-alpha-neuraminyl or NeuAc) from CMP-NeuAc to the non-reducing terminal galactose (Gal) of glycosphingolipids forming gangliosides (important molecules involved in the regulation of multiple cellular processes, including cell proliferation and differentiation, apoptosis, embryogenesis, development, and oncogenesis) (PubMed:16934889, PubMed:9822625). Mainly involved in the biosynthesis of ganglioside GM3 but can also use different glycolipids as substrate accep

LOCALIZAÇÃO

Golgi apparatus membrane

VIAS BIOLÓGICAS (2)
Sialic acid metabolismGlycosphingolipid biosynthesis
MECANISMO DE DOENÇA

Salt and pepper developmental regression syndrome

A rare autosomal recessive disorder characterized by infantile onset of severe, recurrent and refractory seizures, failure to thrive, psychomotor delay, developmental stagnation, and cortical blindness. Deafness is observed in some patients. Affected individuals have patches of skin hypo- or hyperpigmentation on the trunk, face, and extremities.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
31.5 TPM
Glândula adrenal
29.3 TPM
Brain Spinal cord cervical c-1
15.5 TPM
Brain Frontal Cortex BA9
14.9 TPM
Baço
14.6 TPM
OUTRAS DOENÇAS (1)
GM3 synthase deficiency
HGNC:10872UniProt:Q9UNP4
PIGOGPI ethanolamine phosphate transferase 3, catalytic subunitDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Catalytic subunit of the ethanolamine phosphate transferase 3 complex that transfers an ethanolamine phosphate (EtNP) from a phosphatidylethanolamine (PE) to the 6-OH position of the third alpha-1,2-linked mannose of the a 2-acyl-6-[alpha-D-mannosyl-(1->2)-alpha-D-mannosyl-(1->6)-2-phosphoethanolamine-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl]-1-(1-radyl,2-acyl-sn-glycero-3-phospho)-1D-myo-inositol (also termed H6) intermediate to generate a a 2-acyl-6-[6-phosphoethanolamine-alpha-D-mannosyl-

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Hyperphosphatasia with impaired intellectual development syndrome 2

An autosomal recessive form of intellectual disability characterized by facial dysmorphism, brachytelephalangy, and persistent elevated serum alkaline phosphatase (hyperphosphatasia). Some patients may have additional features, such as cardiac septal defects or seizures.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
37.1 TPM
Testículo
29.0 TPM
Ovário
28.3 TPM
Nervo tibial
25.9 TPM
Útero
24.9 TPM
OUTRAS DOENÇAS (2)
hyperphosphatasia with intellectual disability syndrome 2hyperphosphatasia-intellectual disability syndrome
HGNC:23215UniProt:Q8TEQ8
PIGAPhosphatidylinositol N-acetylglucosaminyltransferase subunit ADisease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Catalytic subunit of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis

LOCALIZAÇÃO

Rough endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Paroxysmal nocturnal hemoglobinuria 1

A disorder characterized by hemolytic anemia with hemoglobinuria, thromboses in large vessels, and a deficiency in hematopoiesis. Red blood cell breakdown with release of hemoglobin into the urine is manifested most prominently by dark-colored urine in the morning.

EXPRESSÃO TECIDUAL(Ubíquo)
Pulmão
15.2 TPM
Skin Not Sun Exposed Suprapubic
11.5 TPM
Linfócitos
10.6 TPM
Tireoide
9.4 TPM
Skin Sun Exposed Lower leg
8.8 TPM
OUTRAS DOENÇAS (5)
ferro-cerebro-cutaneous syndromeparoxysmal nocturnal hemoglobinuria 1multiple congenital anomalies-hypotonia-seizures syndrome 2paroxysmal nocturnal hemoglobinuria
HGNC:8957UniProt:P37287
PGAP3GPI-specific phospholipase A2-like PGAP3Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the fatty acid remodeling steps of GPI-anchor maturation where the unsaturated acyl chain at sn-2 of inositol phosphate is replaced by a saturated stearoyl chain (PubMed:17021251, PubMed:24439110). May catalyze the first step of the fatty acid remodeling, by removing the unsaturated acyl chain at sn-2 of inositol phosphate, generating a lyso-GPI intermediate (Probable). The fatty acid remodeling steps is critical for the integration of GPI-APs into lipid rafts (By similarity)

LOCALIZAÇÃO

Golgi apparatus membrane

MECANISMO DE DOENÇA

Hyperphosphatasia with impaired intellectual development syndrome 4

An autosomal recessive neurologic disorder characterized by profound developmental delay, severe intellectual disability, no speech, psychomotor delay, postnatal microcephaly, and elevated serum alkaline phosphatase.

EXPRESSÃO TECIDUAL(Ubíquo)
Tireoide
66.6 TPM
Skin Sun Exposed Lower leg
41.0 TPM
Glândula salivar
38.3 TPM
Skin Not Sun Exposed Suprapubic
37.4 TPM
Cervix Endocervix
36.0 TPM
OUTRAS DOENÇAS (2)
hyperphosphatasia with intellectual disability syndrome 4hyperphosphatasia-intellectual disability syndrome
HGNC:23719UniProt:Q96FM1
PIGWGlucosaminyl-phosphatidylinositol-acyltransferase PIGWDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Acyltransferase that catalyzes the acyl transfer from an acyl-CoA at the 2-OH position of the inositol ring of a 6-(alpha-D-glucosaminyl)-1-(1,2-diacyl-sn-glycero-3-phospho)-1D-myo-inositol (glucosaminyl phosphatidylinositol, GlcN-PI) to generate a 2-acyl-6-alpha-D-glucosaminyl-1-(1,2-diacyl-sn-glycero-3-phospho)-1D-myo-inositol (glucosaminyl acyl phosphatidylinositol, GlcN-(acyl)PI) and participates in the fourth step of GPI-anchor biosynthesis (By similarity). Required for the transport of GPI

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Glycosylphosphatidylinositol biosynthesis defect 11

An autosomal recessive neurologic disorder characterized by developmental delay, intellectual disability, tonic seizures associated with hypsarrhythmia, dysmorphic facial features, and elevated serum alkaline phosphatase.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
13.2 TPM
Fibroblastos
12.7 TPM
Esôfago - Mucosa
10.1 TPM
Skin Sun Exposed Lower leg
9.0 TPM
Skin Not Sun Exposed Suprapubic
8.9 TPM
OUTRAS DOENÇAS (3)
hyperphosphatasia with intellectual disability syndrome 5hyperphosphatasia-intellectual disability syndromehypercoagulability syndrome due to glycosylphosphatidylinositol deficiency
HGNC:23213UniProt:Q7Z7B1
PIGMGPI alpha-1,4-mannosyltransferase I, catalytic subunitDisease-causing germline mutation(s) inModerado
FUNÇÃO

Catalytic subunit of the glycosylphosphatidylinositol-mannosyltransferase I complex which catalyzes the transfer of the first mannose, via an alpha-1,4 bond from a dolichol-phosphate-mannose (Dol-P-Man) to a 2-acyl-6-alpha-D-glucosaminyl-1-(1-radyl,2-acyl-sn-glycero-3-phospho)-1D-myo-inositol (glucosaminyl acyl phosphatidylinositol, GlcN-(acyl)PI) intermediate to generate 2-acyl-6-(alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl)-1-(1-radyl,2-acyl-sn-glycero-3-phospho)-1D-myo-inositol (also termed

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Glycosylphosphatidylinositol biosynthesis defect 1

An autosomal recessive disorder characterized by portal vein thrombosis and portal hypertension, absence seizures, macrocephaly, splenomegaly, cytopenias and early-onset cerebral infarctions.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Spinal cord cervical c-1
12.9 TPM
Fibroblastos
11.1 TPM
Testículo
9.3 TPM
Glândula salivar
8.3 TPM
Cervix Endocervix
8.2 TPM
OUTRAS DOENÇAS (1)
hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency
HGNC:18858UniProt:Q9H3S5
PGAP2Acyltransferase PGAP2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Involved in the fatty acid remodeling steps of GPI-anchor maturation where the unsaturated acyl chain at sn-2 of inositol phosphate is replaced by a saturated stearoyl chain. May catalyze the second step of the fatty acid remodeling, by reacylating a lyso-GPI intermediate at sn-2 of inositol phosphate by a saturated chain (By similarity). The fatty acid remodeling steps is critical for the integration of GPI-APs into lipid rafts (PubMed:23561846)

LOCALIZAÇÃO

Golgi apparatus membrane

MECANISMO DE DOENÇA

Hyperphosphatasia with impaired intellectual development syndrome 3

An autosomal recessive disorder usually characterized by intellectual disability, hypotonia with very poor motor development, poor speech, and increased serum alkaline phosphatase.

EXPRESSÃO TECIDUAL(Ubíquo)
Skin Not Sun Exposed Suprapubic
51.8 TPM
Skin Sun Exposed Lower leg
49.7 TPM
Testículo
46.2 TPM
Tireoide
31.9 TPM
Esôfago - Mucosa
31.1 TPM
OUTRAS DOENÇAS (2)
hyperphosphatasia with intellectual disability syndrome 3hyperphosphatasia-intellectual disability syndrome
HGNC:17893UniProt:Q9UHJ9
PIGNGPI ethanolamine phosphate transferase 1Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Ethanolamine phosphate transferase that catalyzes an ethanolamine phosphate (EtNP) transfer from phosphatidylethanolamine (PE) to the 2-OH position of the first alpha-1,4-linked mannose of a 2-acyl-6-[alpha-D-mannosyl-(1->6)-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl]-1-(1-radyl,2-acyl-sn-glycero-3-phospho)-1D-myo-inositol (also termed H3) intermediate to generate a 2-acyl-6-[alpha-D-mannosyl-(1->6)-2-phosphoethanolamine-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl]-1-(1-radyl,2-acyl-sn-glycer

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Multiple congenital anomalies-hypotonia-seizures syndrome 1

An autosomal recessive disorder characterized by neonatal hypotonia, lack of psychomotor development, seizures, dysmorphic features, and variable congenital anomalies involving the cardiac, urinary, and gastrointestinal systems. Most affected individuals die before 3 years of age.

EXPRESSÃO TECIDUAL(Ubíquo)
Esôfago - Mucosa
6.9 TPM
Fibroblastos
6.7 TPM
Linfócitos
5.5 TPM
Vagina
5.5 TPM
Skin Not Sun Exposed Suprapubic
5.2 TPM
OUTRAS DOENÇAS (2)
multiple congenital anomalies-hypotonia-seizures syndrome 1Fryns syndrome
HGNC:8967UniProt:O95427
PIGYPhosphatidylinositol N-acetylglucosaminyltransferase subunit YDisease-causing germline mutation(s) inTolerante
FUNÇÃO

Part of the glycosylphosphatidylinositol-N-acetylglucosaminyltransferase (GPI-GnT) complex that catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to phosphatidylinositol and participates in the first step of GPI biosynthesis (PubMed:16162815). May act by regulating the catalytic subunit PIGA (PubMed:16162815)

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Hyperphosphatasia with impaired intellectual development syndrome 6

An autosomal recessive, multisystem disorder characterized by severe developmental delay, dysmorphism, seizures, cataracts, and early death in some patients.

OUTRAS DOENÇAS (2)
hyperphosphatasia with intellectual disability syndrome 6hyperphosphatasia-intellectual disability syndrome
HGNC:28213UniProt:Q3MUY2
PIGVGPI alpha-1,6-mannosyltransferase 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Alpha-1,6-mannosyltransferase that catalyzes the transfer of the second mannose, via an alpha-1,6 bond, from a dolichol-phosphate-mannose (Dol-P-Man) to a 2-acyl-6-(alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl)-1-(1-radyl,2-acyl-sn-glycero-3-phospho)-1D-myo-inositol (also termed H2) intermediate to generate a 2-acyl-6-[alpha-D-mannosyl-(1->6)-alpha-D-mannosyl-(1->4)-alpha-D-glucosaminyl]-1-(1-radyl,2-acyl-sn-glycero-3-phospho)-1D-myo-inositol (also termed H3) and participates in the seventh step

LOCALIZAÇÃO

Endoplasmic reticulum membrane

VIAS BIOLÓGICAS (1)
Synthesis of glycosylphosphatidylinositol (GPI)
MECANISMO DE DOENÇA

Hyperphosphatasia with impaired intellectual development syndrome 1

A severe syndrome characterized by elevated serum alkaline phosphatase, severe intellectual disability, seizures, hypotonia, facial dysmorphism, and hypoplastic terminal phalanges.

EXPRESSÃO TECIDUAL(Ubíquo)
Testículo
56.0 TPM
Fibroblastos
16.1 TPM
Útero
15.9 TPM
Glândula adrenal
15.4 TPM
Tireoide
15.2 TPM
OUTRAS DOENÇAS (2)
hyperphosphatasia with intellectual disability syndrome 1hyperphosphatasia-intellectual disability syndrome
HGNC:26031UniProt:Q9NUD9

Variantes genéticas (ClinVar)

488 variantes patogênicas registradas no ClinVar.

🧬 PIGT: GRCh37/hg19 20q11.21-13.12(chr20:31010829-44560369)x1 ()
🧬 PIGT: NM_015937.6(PIGT):c.1595C>A (p.Thr532Lys) ()
🧬 PIGT: NM_015937.6(PIGT):c.1730C>A (p.Pro577Gln) ()
🧬 PIGT: NM_015937.6(PIGT):c.20_22delinsCTT (p.Leu7_Ala8delinsProSer) ()
🧬 PIGT: NM_015937.6(PIGT):c.1646G>T (p.Arg549Leu) ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Alteração do glicosfingolipídio e glicosilação da âncora glicosilfosfatidilinositol

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Alteração do glicosfingolipídio e glicosilação da âncora glicosilfosfatidilinositol.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Alteração do glicosfingolipídio e glicosilação da âncora glicosilfosfatidilinositol

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Ordenadas pelo número de sintomas em comum.

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Neurological Consequences of Congenital Disorders of Glycosylation.
    Advances in neurobiology· 2023· PMID 36255677mais citado
  2. Genetically Engineered Glycosylphosphatidylinositol-Anchored Anti-GD2 Nanobody-Exosome Mimetics for Targeted Osteosarcoma Therapy In Vitro and In Vivo.
    ACS Appl Mater Interfaces· 2025· PMID 41036963recente
  3. Raft-based sphingomyelin interactions revealed by new fluorescent sphingomyelin analogs.
    J Cell Biol· 2017· PMID 28330937recente
  4. Human genetic disorders involving glycosylphosphatidylinositol (GPI) anchors and glycosphingolipids (GSL).
    J Inherit Metab Dis· 2015· PMID 25164783recente
  5. Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease.
    Mol Genet Metab· 2014· PMID 24215843recente
  6. Glycobiology of the Leishmania parasite and emerging targets for antileishmanial drug discovery.
    Expert Opin Ther Targets· 2010· PMID 20536412recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:309515(Orphanet)
  2. MONDO:0017748(MONDO)
  3. GARD:21342(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q55787324(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Compêndio · Raras BR

Alteração do glicosfingolipídio e glicosilação da âncora glicosilfosfatidilinositol

ORPHA:309515 · MONDO:0017748
MedGen
UMLS
C5679954
Wikidata
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades